Access cutting-edge low-grade glioma treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.
Access low-grade glioma specialists in Washington Dc at no cost
This study follows strict safety protocols and ethical guidelines
All study-related low-grade glioma treatment provided free
This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring first-line systemic therapy.
Sponsor: Day One Biopharmaceuticals, Inc.
Check if you qualify for this low-grade glioma clinical trial in Washington Dc, DC
If you're searching for low-grade glioma treatment options in Washington Dc, DC, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced low-grade glioma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.